What Is AOD 9604? (Peptide Fragment Explained)

Fewer than 30% of researchers who order AOD 9604 understand what makes it structurally different from full-length human growth hormone. And that gap matters because the modification determines both its mechanism and its limitations. AOD 9604 (also written as AOD-9604) is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, specifically amino acids 176-191, with a tyrosine added at position 1 to enhance stability. It was developed in the 1990s by Metabolic Pharmaceuticals to retain hGH's lipolytic properties. Fat breakdown. While eliminating the growth-promoting and insulin-disrupting effects that make full hGH problematic for metabolic research.

Our team has guided researchers through peptide selection for metabolic studies across hundreds of protocols. The distinction between a peptide fragment and a full hormone isn't semantic. It's structural, and it determines receptor binding, downstream signalling, and experimental outcomes in ways most suppliers never explain.

What is AOD 9604, and how does it differ from human growth hormone?

AOD 9604 is a 15-amino-acid peptide fragment (hGH 176-191 with an N-terminal tyrosine modification) that mimics the lipolytic activity of human growth hormone without binding to growth hormone receptors. It stimulates lipolysis. The breakdown of stored triglycerides into free fatty acids. Through a mechanism independent of the hGH receptor pathway, avoiding the hyperglycaemia, acromegalic effects, and IGF-1 elevation associated with full-length hGH administration.

The Core Difference: AOD 9604 Is Not Growth Hormone

The name 'AOD 9604' stands for Anti-Obesity Drug, candidate 9604. A designation from its original pharmaceutical development. The compound mirrors a specific 15-residue sequence from the C-terminus of human growth hormone, the region implicated in fat metabolism rather than cellular growth. Critically, AOD 9604 does not bind to growth hormone receptors. Full hGH exerts its effects through GH receptor activation, triggering JAK2-STAT5 signalling that promotes IGF-1 synthesis, protein anabolism, and gluconeogenesis. AOD 9604 bypasses this pathway entirely. It acts on beta-3 adrenergic receptors in adipocytes, directly stimulating hormone-sensitive lipase without upstream receptor engagement.

This structural modification. The truncation to residues 176-191 plus the stabilising tyrosine. Eliminates the mitogenic effects (cell proliferation, cartilage growth) and the diabetogenic effects (impaired glucose tolerance, elevated fasting insulin) that limit hGH use in metabolic research. The peptide retains the lipolytic signal but loses the growth signal. For researchers studying fat oxidation pathways independent of anabolic or glycaemic confounders, that distinction is the entire value proposition. At Real Peptides, every batch of AOD 9604 undergoes HPLC verification to confirm both sequence integrity and the absence of full-length hGH contamination. Because structural purity determines mechanistic specificity.

The Mechanism: How AOD 9604 Stimulates Lipolysis

AOD 9604 activates lipolysis through beta-3 adrenergic receptor agonism in white adipose tissue. When the peptide binds to beta-3 receptors on adipocyte membranes, it triggers a cAMP-PKA signalling cascade that phosphorylates hormone-sensitive lipase (HSL) and perilipin. The proteins that regulate access to stored triglycerides. Phosphorylated HSL translocates to lipid droplets and catalyses the hydrolysis of triglycerides into glycerol and free fatty acids, which are then released into circulation for oxidation in muscle and liver tissue.

Unlike full hGH, which stimulates lipolysis indirectly through IGF-1-mediated insulin antagonism and growth hormone receptor signalling, AOD 9604 acts locally at the adipocyte without requiring IGF-1 elevation or systemic insulin suppression. This produces fat mobilisation without the compensatory glucose elevation that hGH typically triggers. In rodent models, AOD 9604 administration increased serum free fatty acids by 30-40% within two hours without raising blood glucose or insulin. A metabolic profile impossible to achieve with intact hGH. The peptide also demonstrated preferential action on visceral adipose depots over subcutaneous fat in early-phase studies, though depot-specific mechanisms remain under investigation. Research tools like Dihexa allow similar pathway-specific interrogation in other metabolic contexts.

AOD 9604 Research Applications and Limitations

AOD 9604 was originally developed as an anti-obesity pharmaceutical candidate and progressed through Phase II clinical trials in the early 2000s before development was discontinued due to insufficient efficacy in human weight-loss endpoints. Despite this commercial failure, the compound remains valuable in metabolic research for isolating lipolytic signalling from growth and glycaemic pathways. Researchers use AOD 9604 to study beta-3 adrenergic mechanisms, lipid mobilisation kinetics, and adipocyte metabolism in vitro and in animal models where hGH's pleiotropic effects would confound interpretation.

Limitations are significant. The peptide has a short plasma half-life. Approximately 30-60 minutes in rodent models. Requiring frequent dosing or continuous infusion in sustained protocols. It does not promote muscle protein synthesis, bone density, or nitrogen retention; those effects require hGH receptor activation, which AOD 9604 lacks. The clinical trials that terminated its pharmaceutical development found no statistically significant difference in body composition between AOD 9604 and placebo groups after 12 weeks. A result consistent with its narrow mechanism. Lipolysis alone, without corresponding increases in energy expenditure or reductions in caloric intake, does not produce net fat loss. For labs exploring broader metabolic interventions, compounds like Tesofensine offer multi-pathway activity that AOD 9604 cannot replicate.

AOD 9604 vs hGH vs Other Lipolytic Peptides

What If: AOD 9604 Scenarios

What If AOD 9604 Shows No Measurable Lipolytic Effect in My Protocol?

Verify peptide reconstitution and storage first. Lyophilised AOD 9604 must be reconstituted in sterile water or bacteriostatic saline and stored at 2-8°C; any temperature excursion above 8°C degrades the peptide irreversibly. The beta-3 adrenergic receptor expression varies significantly across species and adipose depots. Rodent models show stronger responses than primate models, and visceral fat responds more robustly than subcutaneous fat. If using an in vitro adipocyte model, confirm beta-3 receptor expression through qPCR; some immortalised cell lines lack functional beta-3 receptors entirely. Finally, consider the assay endpoint. AOD 9604 increases free fatty acid release, not necessarily net fat oxidation; without a metabolic sink (exercise, fasting conditions, or pharmacological energy expenditure increase), liberated fatty acids may re-esterify without observable fat loss.

What If I Need to Compare AOD 9604 to Full hGH in the Same Experimental Model?

Run parallel arms with matched dosing schedules, but expect divergent timelines. HGH effects build over days to weeks as IGF-1 synthesis accumulates, while AOD 9604 acts within hours. Measure distinct endpoints: for hGH, track IGF-1, fasting glucose, and nitrogen balance alongside lipolysis markers; for AOD 9604, focus on free fatty acid kinetics, glycerol release, and beta-3 receptor expression without expecting anabolic or glycaemic changes. This design isolates which effects derive from lipolysis alone versus GH receptor-mediated pathways. If comparing body composition outcomes, note that hGH produces lean mass gain that may offset fat loss on a scale, while AOD 9604 has no such anabolic component.

What If the Peptide Arrives as a Liquid Rather Than Lyophilised Powder?

Reject it. AOD 9604 is unstable in aqueous solution at room temperature. Degradation begins within 48-72 hours even under refrigeration. Lyophilised powder stored at -20°C remains stable for 12-24 months; pre-mixed solutions do not. If a supplier ships AOD 9604 pre-reconstituted, it suggests either poor handling protocols or a product that was never lyophilised to begin with. At Real Peptides, every AOD 9604 batch is supplied as lyophilised powder with verified sequence integrity. Pre-mixed peptides are a red flag for compromised stability and unreliable experimental outcomes.

The Structural Truth About AOD 9604

Here's the honest answer: AOD 9604 is not a 'better' or 'safer' version of growth hormone for fat loss. It is a mechanistically distinct compound with a far narrower activity profile. The clinical trials that ended its pharmaceutical development weren't stopped because of safety concerns; they were stopped because the peptide didn't work well enough as a standalone obesity treatment in humans. That failure, however, is what makes it valuable in research. It isolates one specific pathway (beta-3 adrenergic lipolysis) without the confounding variables (IGF-1, insulin resistance, anabolic signalling) that hGH introduces.

Researchers who treat AOD 9604 as 'hGH lite' misunderstand the compound entirely. It doesn't replicate a subset of hGH's effects. It acts through a completely different receptor system. If your protocol requires growth signalling, nitrogen retention, or IGF-1 elevation, AOD 9604 will not deliver those outcomes. If your protocol requires isolated lipolytic stimulation without growth or glucose interference, no other peptide does what AOD 9604 does. The value is in the limitation. Not despite it.

AOD 9604 isn't the compound that failed to become a blockbuster drug. It's the tool that lets you study one metabolic pathway without activating six others. That specificity is exactly why it remains in research catalogues two decades after commercial development stopped. And why structural verification matters more for this peptide than for broader-acting compounds. A contaminated or degraded AOD 9604 sample doesn't just reduce effect size; it introduces the very variables the fragment was designed to eliminate.

All compounds discussed on this page are sold for research use only and are not for human consumption.